A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Epidermolysis Bullosa Simplex

Interventions

DRUG: 5% TolaSure Topical Gel
DRUG: Topical Placebo Gel

Sponsor

BioMendics, LLC

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]